Healthcare > Pharmaceutical8/15/2024 1:00 AM
Watch our webinar with Nyrada, featuring CEO James Bonnar.
The webinar will commence with a presentation, followed by a live Q&A with the audience, providing you the opportunity to ask James any questions about NYR that you may have.
Key topics:
• Nyrada's brain injury program and its core technology
• Non-dilutive funding opportunities
• Success in the Phase I trial
• Upcoming plans in the next 12-18 months
• Near-term catalysts for the company
-----------------
Nyrada is a drug development company specialising in novel treatments for diseases where there is an unmet clinical need, or where current treatments are suboptimal. US incorporated, ASX listed, Australia headquartered, Nyrada is pioneering a family of small molecule drugs that target Transient Receptor Potential Cation (TRPC) channels. Its lead program is a first in class neuroprotection therapy for both traumatic brain injury (TBI) and stroke.